# US 2025/0368702 A1 · Gp96 and use thereof in treating amyotrophic lateral sclerosis

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0368702 A1
- Document ID: US20250368702A1
- Status: Published application
- Kind: A1
- Application number: 18/998,401
- Filed: 2022-11-21
- Published: 2025-12-04
- Earliest claimed: 2022-07-28
- Assignees: Foshan Heat Shock Biotech Co., Ltd.
- Applicants: Foshan Heat Shock Biotech Co., Ltd.
- Inventors: Songdong Meng; Ying Ju; Xin Li; Yuxiu Xu; Fang Cheng; Zihao Wang
- Web page: https://patentgrep.com/patent/US20250368702A1

## CPC

- C07K 14/47: from mammals
- A61K 38/16: Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof {(enzyme inhibitors A61K38/005)}
- A61K 38/17: from animals; from humans {(enzyme inhibitors A61K38/005)}
- A61K 38/1709: {from mammals}
- A61P 21/00: Drugs for disorders of the muscular or neuromuscular system
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- C07K 19/00: Hybrid peptides {, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes}
- C12N 15/62: DNA sequences coding for fusion proteins
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K 2319/00: Fusion polypeptide
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present invention relates to the field of disease treatment. In particular, the present invention provides a gp96 protein and use of a gp96 protein-constructed fusion protein in treating amyotrophic lateral sclerosis. In addition, the present invention further relates to a pharmaceutical composition that can be used for treating one or more of the symptoms of amyotrophic lateral sclerosis, comprising the gp96 protein or the gp96 protein-constructed fusion protein of the present invention.

## Claims

### Claim 1

A method for preventing and/or treating amyotrophic lateral sclerosis in a subject, comprising: administering an effective amount of a gp96 protein or variant thereof or a fusion protein to a subject in need thereof;
wherein, the variant has a sequence identity of at least 90%, such as at least 95%, at least 96%, at least 97%, at least 98%, at least 99%; or, has a substitution (preferably conservative substitution), addition or deletion of one or several (e.g., 1, 2, 3, 4, 5, 6, 7, 8 or 9) amino acids as compared to the gp96 protein, and retains the function of the gp96 protein;
the fusion protein comprises the gp96 protein or variant thereof, and an additional peptide connected to the gp96 protein or variant thereof.

### Claim 2 (depends on 1)

The method according to claim 1, wherein the additional peptide is connected to the N-terminal and/or C-terminal of the gp96 protein or variant thereof, optionally via a linker (e.g., a peptide linker);
preferably, the additional peptide is connected to the N-terminal of the gp96 protein or variant thereof.

### Claim 3 (depends on 1)

The method according to claim 1, wherein the additional peptide is a flexible peptide;
preferably, the additional peptide comprises one or more glycine (G).

### Claim 4 (depends on 1)

The method according to claim 1, which has one or more features selected from the group consisting of:
(i) the gp96 protein comprises or consists of an amino acid sequence as set forth in SEQ ID NO: 1 or 2;
(ii) the fusion protein comprises or consists of an amino acid sequence as set forth in SEQ ID NO: 4;
(iii) the gp96 protein or variant thereof or the fusion protein may further comprise an additional protein tag, a targeting moiety or any combination thereof.

### Claim 5 (depends on 1)

The method according to claim 1, which is used for one or more of the following:
(1) inducing a regulatory T cell;
(2) inhibiting the generation of a Th17 cell;
(3) inducing an increase in the number of Th2 cell;
(4) inhibiting the generation of a Th1 cell;
(5) reducing reactive oxygen species and oxidative stress in a motor neuron;
(6) reducing the expression of SOD1;
(7) restoring the function of dysfunctional mitochondria in a motor neuron;
(8) reducing denatured protein in a cell;
(9) reducing creatine kinase level and/or inhibiting creatine kinase activity, and upregulating creatine level;
(10) promoting the production of nerve growth factor;
(11) promoting the growth of a diseased motor nerve axon;
(12) improving axonal transport capacity.

### Claim 6

(canceled)

### Claim 7

(canceled)

### Claim 8

A fusion protein, comprising a gp96 protein or variant thereof, and an additional peptide linked to the gp96 protein or variant thereof;
wherein, the variant has a sequence identity of at least 90%, such as at least 95%, at least 96%, at least 97%, at least 98%, at least 99%; or, has a substitution (preferably conservative substitution), addition or deletion of one or several (e.g., 1, 2, 3, 4, 5, 6, 7, 8 or 9) amino acids as compared to the gp96 protein, and retains the function of the gp96 protein;
the additional peptide is linked to the N-terminal and/or C-terminal of the gp96 protein or variant thereof, optionally via a linker (e.g., a peptide linker); and the additional peptide has a structure as shown in (GGGGS)n1C(GGGGS)n2, wherein the n1 and n2 are each independently selected from: 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10.

### Claim 9 (depends on 8)

The fusion protein according to claim 8, which has one or more features selected from the group consisting of:
(i) the gp96 protein comprises or consists of an amino acid sequence as set forth in SEQ ID NO: 1 or 2;
(ii) the fusion protein comprises or consists of an amino acid sequence as set forth in SEQ ID NO: 4;
(iii) the fusion protein may further comprise an additional protein tag, a targeting moiety or any combination thereof.

### Claim 10 (depends on 8)

An isolated nucleic acid molecule, encoding the fusion protein according to claim 8.

### Claim 11 (depends on 10)

A vector, comprising the isolated nucleic acid molecule according to claim 10; preferably, the vector is a cloning vector or an expression vector.

### Claim 12 (depends on 10)

A host cell, comprising the isolated nucleic acid molecule according to claim 10 or a vector comprising the isolated nucleic acid molecule.

### Claim 13 (depends on 12)

A method for preparing a fusion protein, comprising culturing the host cell according to claim 12 under a condition that allows protein expression, and recovering the fusion protein from a culture of the cultured host cell.

### Claim 14 (depends on 8)

A pharmaceutical composition, comprising the fusion protein according to claim 8, an isolated nucleic acid molecule or vector or host cell comprising a nucleotide sequence encoding the fusion protein, and a pharmaceutically acceptable carrier and/or excipient;
preferably, the pharmaceutical composition optionally further comprises an additional pharmaceutically active agent;
preferably, the additional pharmaceutically active agent is a drug having the effect of treating amyotrophic lateral sclerosis.

### Claim 15

(canceled)

### Claim 16 (depends on 8)

A method for preventing and/or treating amyotrophic lateral sclerosis, comprising: administering an effective amount of (i) the fusion protein according to claim 8, or (ii) an isolated nucleic acid molecule or vector or host cell comprising a nucleotide sequence encoding the fusion protein, or (iii) a pharmaceutical composition comprising any of the foregoing and a pharmaceutically acceptable carrier and/or excipient, to a subject in need thereof.

### Claim 17 (depends on 1)

The method according to claim 1, wherein the additional peptide has a structure as shown in (GGGGS)n1C(GGGGS)n2, wherein the n1 and n2 are each independently selected from: 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10.

### Claim 18 (depends on 17)

The method according to claim 17, wherein the n1 and n2 are not 0 at the same time.

### Claim 19 (depends on 1)

The method according to claim 1, wherein the additional peptide has an amino acid sequence as set forth in SEQ ID NO: 6.

### Claim 20 (depends on 8)

The fusion protein according to claim 8, wherein the n1 and n2 are not 0 at the same time.

### Claim 21 (depends on 8)

The fusion protein according to claim 8, wherein the additional peptide has an amino acid sequence as set forth in SEQ ID NO: 6.

### Claim 22 (depends on 16)

The method according to claim 16, which is used for one or more of the following:
(1) inducing a regulatory T cell;
(2) inhibiting the generation of a Th17 cell;
(3) inducing an increase in the number of a Th2 cell;
(4) inhibiting the generation of a Th1 cell;
(5) reducing reactive oxygen species and oxidative stress in a motor neuron;
(6) reducing the expression of SOD1;
(7) restoring the function of dysfunctional mitochondria in a motor neuron;
(8) reducing denatured protein in a cell;
(9) reducing creatine kinase level and/or inhibiting creatine kinase activity, and upregulating creatine level;
(10) promoting the production of nerve growth factor;
(11) promoting the growth of a diseased motor nerve axon;
(12) improving the transport capacity of an axon.
